|
1
|
National Cancer Institute: SEER Stat Fact
Sheets: Acute Myeloid Leukemia (AML). NIH. http://seer.cancer.gov/statfacts/html/amyl.html.
Accessed May 19. 2016
|
|
2
|
Irish JM, Anensen N, Hovland R, Skavland
J, Borresen-Dale A-L, Bruserud O, Nolan GP and Gjertsen BT: Flt3
Y591 duplication and Bcl-2 overexpression are detected in acute
myeloid leukemia cells with high levels of phosphorylated wild-type
p53. Blood. 109:2589–2596. 2007. View Article : Google Scholar
|
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Delbridge AR, Grabow S, Strasser A and
Vaux DL: Thirty years of BCL-2: Translating cell death discoveries
into novel cancer therapies. Nat Rev Cancer. 16:99–109. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsujimoto Y, Cossman J, Jaffe E and Croce
CM: Involvement of the bcl-2 gene in human follicular lymphoma.
Science. 228:1440–1443. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cleary ML, Smith SD and Sklar J: Cloning
and structural analysis of cDNAs for bcl-2 and a hybrid
bcl-2/immunoglobulin transcript resulting from the t(14;18)
translocation. Cell. 47:19–28. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vaux DL, Cory S and Adams JM: Bcl-2 gene
promotes haemopoietic cell survival and cooperates with c-myc to
immortalize pre-B cells. Nature. 335:440–442. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang JZ, Sanger WG, Greiner TC, Staudt
LM, Weisenburger DD, Pickering DL, Lynch JC, Armitage JO, Warnke
RA, Alizadeh AA, et al: The t(14;18) defines a unique subset of
diffuse large B-cell lymphoma with a germinal center B-cell gene
expression profile. Blood. 99:2285–2290. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Minn AJ, Rudin CM, Boise LH and Thompson
CB: Expression of bcl-xL can confer a multidrug resistance
phenotype. Blood. 86:1903–1910. 1995.PubMed/NCBI
|
|
10
|
Pan R, Hogdal LJ, Benito JM, Bucci D, Han
L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, et al:
Selective BCL-2 inhibition by ABT-199 causes on-target cell death
in acute myeloid leukemia. Cancer Discov. 4:362–375. 2014.
View Article : Google Scholar
|
|
11
|
Ni Chonghaile T and Letai A: Mimicking the
BH3 domain to kill cancer cells. Oncogene. 27(Suppl 1): S149–S157.
2008. View Article : Google Scholar
|
|
12
|
Merino D, Khaw SL, Glaser SP, Anderson DJ,
Belmont LD, Wong C, Yue P, Robati M, Phipson B, Fairlie WD, et al:
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737
and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood.
119:5807–5816. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Del Gaizo Moore V, Schlis KD, Sallan SE,
Armstrong SA and Letai A: BCL-2 dependence and ABT-737 sensitivity
in acute lymphoblastic leukemia. Blood. 111:2300–2309. 2008.
View Article : Google Scholar
|
|
14
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges
J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tse C, Shoemaker AR, Adickes J, Anderson
MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et
al: ABT-263: A potent and orally bioavailable Bcl-2 family
inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gavathiotis E, Suzuki M, Davis ML, Pitter
K, Bird GH, Katz SG, Tu H-C, Kim H, Cheng EH-Y, Tjandra N, et al:
BAX activation is initiated at a novel interaction site. Nature.
455:1076–1081. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Konopleva M, Contractor R, Tsao T, Samudio
I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi Y-X, Sneed T, et al:
Mechanisms of apoptosis sensitivity and resistance to the BH3
mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Souers AJ, Leverson JD, Boghaert ER,
Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH,
Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2
inhibitor, achieves antitumor activity while sparing platelets. Nat
Med. 19:202–208. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vandenberg CJ and Cory S: ABT-199, a new
Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive
Myc-driven mouse lymphomas without provoking thrombocytopenia.
Blood. 121:2285–2288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roberts AW, Davids MS, Pagel JM, Kahl BS,
Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR,
Gressick L, et al: Targeting BCL2 with venetoclax in relapsed
chronic lymphocytic leukemia. N Engl J Med. 374:311–322. 2016.
View Article : Google Scholar
|
|
21
|
San-Miguel JF: Consolidation therapy in
myeloma: A consolidated approach? Blood. 120:2–3. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roberts AW, Advani RH, Kahl BS, Persky D,
Sweetenham JW, Carney DA, Yang J, Busman TB, Enschede SH,
Humerickhouse RA, et al: Phase 1 study of the safety,
pharmacokinetics, and anti-tumour activity of the BCL2 inhibitor
navitoclax in combination with rituximab in patients with relapsed
or refractory CD20 lymphoid malignancies. Br J Haematol.
170:669–678. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li T, Yuan G, Zhang L, Ye L, Li S, Fan Y
and Sun J: ApoG2 inhibits the antiapoptotic protein, Mcl1, and
induces mitochon-driadependent apoptosis in human colorectal cancer
cells. Mol Med Rep. 12:6976–6984. 2015.PubMed/NCBI
|
|
24
|
Ye L, Yuan G, Xu F, Sun Y, Chen Z, Chen M,
Li T, Sun P, Li S and Sun J: The small-molecule compound BM-1197
inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers
apoptotic cell death in human colorectal cancer cells. Tumour Biol.
36:3447–3455. 2015. View Article : Google Scholar
|
|
25
|
Bai L, Chen J, Liu L, McEachern D, Aguilar
A, Zhou H, Yang CY, Wang H, Wen J, Wang G, et al: BM-1252
(APG-1252): A potent dual specific Bcl-2/Bcl-xL inhibitor that
achieves complete tumor regression with minimal platelet toxicity.
Eur J Cancer. 50:109–110. 2014. View Article : Google Scholar
|
|
26
|
Wang H, Wang G, Du Z, Wu M, McEachern D,
Aguilar A, Lin Y, Lin X, Wen J, Gu L, et al: Preclinical studies of
a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor
efficacy and significantly reduced platelet toxicity. Eur J Cancer.
50:176–177. 2014. View Article : Google Scholar
|
|
27
|
Glaser SP, Lee EF, Trounson E, Bouillet P,
Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, et
al: Anti-apoptotic Mcl-1 is essential for the development and
sustained growth of acute myeloid leukemia. Genes Dev. 26:120–125.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Högstrand K, Hejll E, Sander B, Rozell B,
Larsson LG and Grandien A: Inhibition of the intrinsic but not the
extrinsic apoptosis pathway accelerates and drives MYC-driven
tumorigenesis towards acute myeloid leukemia. PLoS One.
7:e313662012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Del Poeta G, Venditti A, Del Principe MI,
Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A,
Mazzone C, et al: Amount of spontaneous apoptosis detected by
Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).
Blood. 101:2125–2131. 2003. View Article : Google Scholar
|
|
30
|
Roberts AW, Seymour JF, Brown JR, Wierda
WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DCS, Xiong H, et al:
Substantial susceptibility of chronic lymphocytic leukemia to BCL2
inhibition: Results of a phase I study of navitoclax in patients
with relapsed or refractory disease. J Clin Oncol. 30:488–496.
2012. View Article : Google Scholar
|
|
31
|
Ackler S, Mitten MJ, Foster K, Oleksijew
A, Refici M, Tahir SK, Xiao Y, Tse C, Frost DJ, Fesik SW, et al:
The Bcl-2 inhibitor ABT-263 enhances the response of multiple
chemotherapeutic regimens in hematologic tumors in vivo. Cancer
Chemother Pharmacol. 66:869–880. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stilgenbauer S, Eichhorst B, Schetelig J,
Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner C-M, Roberts
AW, Jurczak W, et al: Venetoclax in relapsed or refractory chronic
lymphocytic leukaemia with 17p deletion: A multicentre, open-label,
phase 2 study. Lancet Oncol. 17:768–778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar
|
|
34
|
Liu X, Kim CN, Yang J, Jemmerson R and
Wang X: Induction of apoptotic program in cell-free extracts:
Requirement for dATP and cytochrome c. Cell. 86:147–157. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: Release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kluck RM, Bossy-Wetzel E, Green DR and
Newmeyer DD: The release of cytochrome c from mitochondria: A
primary site for Bcl-2 regulation of apoptosis. Science.
275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Willis SN and Adams JM: Life in the
balance: How BH3-only proteins induce apoptosis. Curr Opin Cell
Biol. 17:617–625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wei MC, Zong WX, Cheng EH, Lindsten T,
Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and
Korsmeyer SJ: Proapoptotic BAX and BAK: A requisite gateway to
mitochondrial dysfunction and death. Science. 292:727–730. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Czabotar PE, Westphal D, Dewson G, Ma S,
Hockings C, Fairlie WD, Lee EF, Yao S, Robin AY, Smith BJ, et al:
Bax crystal structures reveal how BH3 domains activate Bax and
nucleate its oligomerization to induce apoptosis. Cell.
152:519–531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dewson G and Kluck RM: Mechanisms by which
Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci.
122:2801–2808. 2009. View Article : Google Scholar : PubMed/NCBI
|
